ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase II drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ITM-91 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ITM-91 overview
ITM-91 is under development for the treatment of unresectable locally advanced or metastatic solid tumors including renal cell carcinoma, pancreatic ductal adenocarcinoma, colorectal cancer. The drug candidate comprises of PurAffin ligands which are chemically stabilized peptide ligands (peptidomimetics) coupled to a therapeutic radioisotope via a linker and radioconjugated to a chelator. The drug candidate is developed based on PurAffin technology. It is administered through intravenous route. It is a radioligand therapy.
It was under development for the treatment of mesothelioma (malignant mesothelioma).
ITM Isotope Technologies Munich overview
ITM Isotope Technologies Munich (ITM) is a biotechnology company that develops and produces therapeutic and diagnostic radiopharmaceuticals and radioisotopes to treat cancer. Its pipeline product portfolio includes, ITM-64D for stomatostatin receptor tumors, ITM-14D for gastro entero pancreatic- neuro endocrine tumors, ITM-24D, 23, 22 for prostate cancer, ITM-51, 52 for ovarian cancer, adenocarcinoma, ITM-51, 52 for ovarian cancer, adenocarcinoma, ITM-80 for neuro endocrine tumors and others. It has laboratories manufacturing radiopharmaceuticals. ITM is headquartered in Munich, Bavaria, Germany.
For a complete picture of ITM-91’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
